FONR FONAR CORP

NEUTRAL Impact: 3/10 DEFA14A
Horizon days Filed May 21, 2026 Processed 22d 14h ago SEC 0001193125-26-234921
Proxy solicitation materials
Latest settled — T+5d ⚠ clustered
FONR ▲ +1.14% at T+5d
NEUTRAL call ✓ call won +1.14% · α vs SPY -0.52% · entry $18.90 → $19.11
Next anchor: T+20d in 9d
Latest observation: T+8 +0.53% FF3 residual α
Entry anchored
May 21, 2026
via day open
T+1d
+0.08%
call +0.08% · α -0.51%
$18.91
settled 22d ago
T+5d
+1.14%
call +1.14% · α -0.52%
$19.11
settled 15d ago
T+20d
call — · α —
in 9d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

FONAR filed additional definitive proxy materials to supplement disclosures for its planned going-private merger, responding to stockholder lawsuits alleging deficient disclosures. The special meeting to vote on the merger is scheduled for May 28, 2026. The supplemental disclosures include timeline details, confirmation that non-disclosure agreements did not contain 'don't ask-don't waive' standstills, and additional financial projections from Marshall & Stevens.

Actionable Insight

The merger vote is one week away. Monitor for shareholder approval and any last-minute legal challenges. The supplemental disclosures reduce litigation risk but do not alter the merger price or likelihood of completion.

Key Facts

  • Special meeting to vote on merger scheduled for May 28, 2026.
  • Company voluntarily supplements proxy statement in response to lawsuits alleging deficient disclosures.
  • No new financial terms of the merger are disclosed.
  • Marshall & Stevens estimated liquidation value of common equity at approximately $14.63 per share.
  • CEO Timothy Damadian controls the buyer entities, creating a potential conflict of interest.

Financial Impact

No new financial magnitude; supplemental disclosures do not change merger consideration.

Risk Factors

  • Shareholders may reject the merger despite supplemental disclosures.
  • Litigation could still delay or block the transaction.
  • Management conflict of interest (CEO buying out public shareholders, no competing bids solicited).

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-234921
Document: 0001193125-26-234921-index-headers.html0001193125-26-234921
Document: 0001193125-26-234921-index.html0001193125-26-234921
Document: 0001193125-26-234921.txt0001193125-26-234921
5 reports for FONR
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for FONR — sortable, filterable
Type Now
Jun 3, 2026
9d ago
8-K
NEUTRAL ★ 7/10
$19.09 awaiting T+5awaiting T+5
May 21, 2026
22d ago
DEFA14A
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%
May 21, 2026
22d ago
8-K
NEUTRAL ★ 3/10
$18.90 $19.11▲ +1.14%▼ −0.52%
May 12, 2026
4w ago
DEFA14A
BEARISH ★ 7/10
$18.86 $18.86· 0.00%▼ −1.16%
May 12, 2026
4w ago
8-K
BEARISH ★ 6/10
$18.86 $18.86· 0.00%▼ −1.16%
Showing 5 of 5

US Market Status

Market Closed — Opens Mon (49h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access